(Information sent by the signatory company)
Funding from the Bill & Melinda Gates Foundation will go toward understanding the benefits of new cap analogs for therapeutic applications.
WARSAW, Poland, Dec. 8, 2022 /PRNewswire/ -- ExPLoRNA Therapeutics, a Polish biotech company revolutionizing vaccines and mRNA therapy with unprecedented translational efficiency, has received funding from the Bill & Melinda Gates Foundation to further develop its unique mRNA technology. ExPLoRNA specializes in novel cap analogues, the initial part of the mRNA that is crucial to enable the successful production of the encoded protein. The ExPLoRNA technology increases protein production beyond the scale observable thus far with other standard cap analogs.
Total funding received from the Bill & Melinda Gates Foundation is $813,578 and will be used for a 14-month project. The project aims to better understand the benefits of ExPLoRNA cap analogues, especially in terms of reducing the mRNA dose required for therapeutic effects in vaccination and monoclonal antibody production settings.
Planned experiments include the use of state-of-the-art, clinically validated lipid nanoparticle (LNP) formulations from Acuitas Therapeutics. Acuitas is known for its successful role in providing the LNP technology for one of only two mRNA-based COVID-19 vaccines approved by regulatory authorities.
ExPLoRNA Therapeutics is the first Polish biotech company to receive funding from the Bill & Melinda Gates Foundation. Through this project, ExPLoRNA Therapeutics is committed to its vision of making mRNA technology more accessible in low-income countries to help fight diseases that threaten people's lives and well-being.
"We are grateful for the foundation's support in helping us achieve our vision. With the help of this grant, we intend to accelerate the development of future vaccines and mRNA therapies," said Jacek Jemielity, CEO of ExPLoRNA Therapeutics and professor from the University of Warsaw.
About ExPLoRNA Therapeutics
With passion, ExPLoRNA Therapeutics (www.explorna.com) leverages over 20 years of cap analog research and develops breakthrough mRNA innovations as a therapeutic platform, applies those solutions into unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners. .
About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company specializing in the development of delivery systems for lipid nanoparticle-based nucleic acid therapies. The team works with partners to develop new therapies to address unmet clinical needs based on their internationally recognized capabilities in delivery technology.
Logo - https://mma.prnewswire.com/media/1963546...
View original content: https://www.prnewswire.com/news-releases/explorna-therapeutics-recibe-financiacion-para-avanzar-en-su-novedosa-tecnologia-de-arnm-301697243.html
